CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Novo Nordisk A/S

NVO
$169.85BLarge Cap

Next catalyst

Phase 2December 2026

NNC0662-0419

Overweight

Get an email about NVO's next catalysts

Track Novo Nordisk A/S (NVO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 19 more upcoming events in our data (NDA filing, Phase 2 readout, Phase 3 readout and more).See the timeline

Catalyst Timeline

20 upcoming, 1 past

Phase 2Next

NNC0662-0419 Phase 2 Est. Readout

December 2026~NNC0662-0419224

Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight

Source
NDA Filing

NDA Filing - etavopivat

December 2026~Etavopivat

For sickle cell disease. Novo Nordisk's etavopivat demonstrated significant efficacy in late-stage sickle cell disease trials with a 27% reduction in vaso-occlusive crises and 48.7% hemoglobin response. The company plans to seek FDA approval in the second half of 2026.

Phase 2

UBT251 Phase 2 Est. Readout

January 2027~UBT251333

Primary completion for UBT251 trial (NCT07395687) in Overweight

Source
Phase 3

Insulin icodec Phase 3 Est. Readout

January 2027~Insulin Icodec877

Estimated primary completion for Insulin icodec trial (NCT07076199) in Diabetes Mellitus, Type 1. Topline data typically follows completion by weeks to months.

Source
Phase 3

Ziltivekimab Phase 3 Est. Readout (ARTEMIS)

January 2027~Ziltivekimab10,000

Estimated primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk. Topline data typically follows completion by weeks to months.

Source
Phase 3

CagriSema (Cagrilintide B and Semaglutide I) Phase 3 Est. Readout

March 2027~CagriSema (Cagrilintide B and Semaglutide I)609

Estimated primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT07011667) in Obesity. Topline data typically follows completion by weeks to months.

Source
Other

Other - Wegovy

April 2027~

For weight management. Novo Nordisk announced significant reductions in US list prices for Wegovy, Ozempic, and Rybelsus (semaglutide medicines) effective January 1, 2027, as part of efforts to expand patient access.

Phase 3

Cagrilintide Phase 3 Est. Readout (RENEW 2)

May 2027~Cagrilintide330

Primary completion for Cagrilintide trial (NCT07220642) in Obesity

Source

How NVO's past catalysts played out

Market Overview

Stock performance and key metrics

NYSEPharmaceutical PreparationsPharmaceuticals🇺🇸EuropeBAGSVAERD DENMARK66.7K employees

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.

Website
Drug Pipeline

oral anti-diabetic drug

Phase 3

Diabetes

exenatide

Phase 3

Diabetes

repaglinide and metformin combination tablet

Phase 3

Diabetes

NNC0487-0111

Phase 3

Obesity

Insulin glargine U100

Phase 3

Diabetes Mellitus, Type 2

repaglinide

Phase 3

Diabetes

biphasic human insulin 50

Phase 3

Diabetes

insulin human

Phase 3

Diabetes

inhaled human insulin

Phase 3

Diabetes

Etavopivat

Phase 3

Sickle Cell Disease

CagriSema (Cagrilintide B and Semaglutide I)

Phase 3

Obesity

Canagliflozin

Phase 3

Diabetes

sulfonylurea

Phase 3

Diabetes

vatreptacog alfa (activated)

Phase 3

Congenital Bleeding Disorder

Efruxifermin

Phase 3

NASH - Nonalcoholic Steatohepatitis

biphasic insulin aspart 70

Phase 3

Diabetes

17-beta estradiol

Phase 3

Genetic Disorder

Saxenda

Phase 3

Obesity

estradiol

Phase 3

Menopause

Semagludtide

Phase 3

Early Alzheimer's Disease

Etavopivat Tablets High dose

Phase 3

Sickle Cell Disease

Insulin Fiasp

Phase 3

Type 2 Diabetes Treated With Insulin

Etavopivat Tablets

Phase 3

Sickle Cell Disease

glibenclamide

Phase 3

Diabetes

eptacog alfa (activated)

Phase 3

Acquired Bleeding Disorder

Cagrisema

Phase 3

Obesity

Etavopivat B

Phase 3

Sickle Cell Disease

Etavopivat C

Phase 3

Sickle Cell Disease

Norditropin

Phase 3

Growth Hormone Disorder

IDegLira

Phase 3

Diabetes Mellitus

Insulin infusion with a goal

Phase 3

Cardiac Surgical Procedures

Hemohes® (Hydroxyethyl starch)

Phase 3

Severe Sepsis

Etavopivat Tablets Low dose

Phase 3

Sickle Cell Disease

nexium

Phase 3

Type 2 Diabetes

Liraglutide Pen Injector

Phase 3

Pre Diabetes

Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin

Phase 3

Diabetes Mellitus, Type 1

Insulin Asparte

Phase 3

Cystic Fibrosis

Zenagamtide

Phase 3

Type 2 Diabetes

estradiol/norethisterone acetate (NETA)

Phase 3

Menopause

biphasic human insulin 30

Phase 3

Diabetes

Estradiol Vaginal

Phase 3

Vulvovaginal Atrophy

Recombinant Activated Factor VII (rFVIIa)

Phase 3

Intracerebral Hemorrhage

insulin

Phase 3

Diabetes

Metformin XR plus liraglutide

Phase 3

Gestational Diabetes Mellitus

insulin glargine

Phase 3

Diabetes

Metformin on top of intensive insulin therapy

Phase 3

Type 2 Diabetes Mellitus

Recombinant Factor VIIa

Phase 3

Intracerebral Hemorrhage

SOMATROPINE* : Norditropine® simplexx®

Phase 3

Anorexia Nervosa

NovoLog

Phase 3

Type 2 Diabetes Treated With Insulin

Ziltivekimab C

Phase 3

Cardiovascular Risk

rosiglitazone and metformin combination tablet

Phase 3

Diabetes

biphasic insulin aspart

Phase 3

Diabetes

Cagrilintide

Phase 3

Obesity or Overweight

Concizumab

Phase 3

Congenital Bleeding Disorder

biphasic human insulin

Phase 3

Diabetes

Insulin Icodec

Phase 3

Diabetes Mellitus, Type 2

human insulin

Phase 3

Diabetes

insulin NPH

Phase 3

Diabetes

turoctocog alfa pegol

Phase 3

Congenital Bleeding Disorder

rosiglitazone

Phase 3

Diabetes

biphasic insulin aspart 50

Phase 3

Diabetes

DPP-4 inhibitor

Phase 3

Diabetes

NNC0365-3769 (Mim8)

Phase 3

Haemophilia A

Norditropin®

Phase 3

Growth Hormone Deficiency in Children

Ziltivekimab B

Phase 3

Cardiovascular Risk

NNC0365-3769 (Mim8) PPX

Phase 3

Haemophilia A

Faster aspart

Phase 3

Diabetes Mellitus, Type 1

basal insulin

Phase 3

Diabetes

Etavopivat A

Phase 3

Sickle Cell Disease

sulphonylurea

Phase 3

Diabetes

nonacog beta pegol

Phase 3

Congenital Bleeding Disorder

NPH insulin

Phase 3

Diabetes

Turoctocog alfa

Phase 3

Haemostasis

Insuline glargine U100 (reduced)

Phase 3

Diabetes Mellitus, Type 2

Ziltivekimab

Phase 3

Heart Failure

Oral semaglutide

Phase 3

Diabetes Mellitus, Type 2

Faster-acting insulin aspart

Phase 3

Diabetes

somapacitan

Phase 3

Adult Growth Hormone Deficiency

human soluble insulin

Phase 3

Diabetes

NNC6019-0001

Phase 3

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Mim8

Phase 3

Haemophilia A

IcoSema

Phase 3

Type 2 Diabetes

insulin detemir

Phase 3

Diabetes

somatropin

Phase 3

Growth Hormone Disorder

biphasic insulin aspart 30

Phase 3

Diabetes

activated recombinant human factor VII

Phase 3

Acquired Bleeding Disorder

Semaglutide

Phase 3

Obesity

insulin aspart

Phase 3

Diabetes

insulin degludec/liraglutide

Phase 3

Diabetes

insulin degludec

Phase 3

Diabetes

catridecacog

Phase 3

Congenital Bleeding Disorder

liraglutide

Phase 3

Diabetes

insulin degludec/insulin aspart

Phase 3

Diabetes

insulin lispro

Phase 3

Diabetes

Semaglutide J

Phase 3

Diabetes Mellitus, Type 2

turoctocog alfa pegol (N8-GP)

Phase 3

Haemophilia A

DCR-PHXC

Phase 3

Primary Hyperoxaluria Type 1 (PH1)

CDR132L

Phase 2

Heart Failure

NNC0114-0006

Phase 2

Diabetes

NNC109-0012

Phase 2

Inflammation

NNC0194-0499

Phase 2

Alcohol-related Liver Disease

NNC0385-0434 A

Phase 2

Atherosclerotic Cardiovascular Disease

NNC0480-0389

Phase 2

Diabetes Mellitus, Type 2

COR-001

Phase 2

Anemia

Semaglutide (administered by PDS290 pen)

Phase 2

Healthy Volunteers Diabetes Mellitus, Type 2

autologous stored platelets

Phase 2

Bleeding

insulin 338 (GIPET I)

Phase 2

Diabetes

Cagrilintide + semaglutide

Phase 2

Alcohol-related Liver Disease

NNC0662-0419

Phase 2

Overweight

NNC126-0083

Phase 2

Growth Hormone Disorder

EX1000

Phase 2

Diabetes

orlistat

Phase 2

Metabolism and Nutrition Disorder

Eptacog alfa

Phase 2

Congenital Bleeding Disorder

NNC0519-0130

Phase 2

Diabetes Mellitus, Type 2

UBT251

Phase 2

Overweight

nedosiran

Phase 2

Primary Hyperoxaluria

activated recombinant human factor VII, long acting

Phase 2

Congenital Bleeding Disorder

NNC0174 0833

Phase 2

Non-alcoholic Steatohepatitis

NNC0194 0499

Phase 2

Non-alcoholic Steatohepatitis

Fast-acting insulin aspart

Phase 2

Diabetes Mellitus, Type 1

Semaglutide and NNC0165-1875

Phase 2

Obesity

Norditropin SimpleXx (growth hormone)

Phase 2

Growth Hormone Deficiency

NNC0090-2746

Phase 2

Diabetes

Regular Human Insulin

Phase 2

Type 2 Diabetes Mellitus

Semaglutide Pen Injector

Phase 2

NAFLD

recombinant interleukin-21

Phase 2

Cancer

NNC 0151-0000-0000

Phase 2

Inflammation

Firsocostat

Phase 2

Nonalcoholic Steatohepatitis

NDec - oral decitabine-tetrahydrouridine

Phase 2

Sickle Cell Disease

GlucoNorm

Phase 2

Type 2 Diabetes

Semaglutide (SEMA)

Phase 2

Nonalcoholic Steatohepatitis

Semaglutide (administered by DV3396 pen)

Phase 2

Healthy Volunteers Diabetes Mellitus, Type 2

Dasatinib

Phase 2

Osteopenia, Osteoporosis

caelyx (pegylated liposomal doxorubicin)

Phase 2

Cancer

Everolimus (Afinitor®)

Phase 2

Postmenopausal Women

somatotropin

Phase 2

Muscular Atrophy, Spinal

Norditropin® FlexPro® pen

Phase 2

Growth Hormone Disorder

intensive insulin therapy to maintain normoglycemia

Phase 2

Critical Illness

Cilofexor

Phase 2

Nonalcoholic Steatohepatitis

NNC0487-0111 subcutanous

Phase 2

Type 2 Diabetes (T2D)

Mixed Meal Tolerance Test with paracetamol

Phase 2

Type 1 Diabetes Mellitus

NNC0487-0111 oral

Phase 2

Type 2 Diabetes (T2D)

Actrapid HM

Phase 2

Diabetes, Type I

Growth Hormone

Phase 2

TBI (Traumatic Brain Injury)

Dipeptidyl peptidase-4 inhibitors

Phase 2

Diabetes Mellitus, Type 2

Dobutamine

Phase 2

Acute Myocardial Infarction

NNC0174-0833

Phase 2

Overweight

diabetes

9 drugs in this indication

obesity

2 drugs in this indication

Diabetes Mellitus, Type 2

2 drugs in this indication

Congenital Bleeding Disorder

2 drugs in this indication

Haemophilia A

2 drugs in this indication

weight management

2 drugs in this indication

CKD

1 drug in this indication

gastric issues

1 drug in this indication

MACE risk reduction

1 drug in this indication

hemophilia A

1 drug in this indication

Obesity or Overweight

1 drug in this indication

Heart Failure

1 drug in this indication

Inflammation

1 drug in this indication

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

1 drug in this indication

obesity, overweight

1 drug in this indication

Overweight

1 drug in this indication

weight reduction

1 drug in this indication

idiopathic short stature in children

1 drug in this indication

obesity with excess liver fat

1 drug in this indication

haemophilia A, with or without inhibitors in adults and children

1 drug in this indication

obesity-related heart failure with preserved ejection fraction (HF-pEF) and type 2 diabetes

1 drug in this indication

weight loss

1 drug in this indication

Healthy Volunteers Diabetes Mellitus, Type 2

1 drug in this indication

Growth Hormone Deficiency in Children

1 drug in this indication

Type 2 diabetes in children 10 years of age and older

1 drug in this indication

MASH (metabolic dysfunction-associated steatohepatitis)

1 drug in this indication

obesity/weight management

1 drug in this indication

sickle cell disease

1 drug in this indication

weight loss/chronic weight management

1 drug in this indication

sickle cell disease (adolescents and adults)

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Novo Nordisk A/S's drug pipeline?→

CatalystAlert tracks 147 drug candidates in Novo Nordisk A/S's (NVO) pipeline across Phase 3, Phase 2. Its lead program is Etavopivat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Novo Nordisk A/S's next FDA catalyst?→

Novo Nordisk A/S's (NVO) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track NVO biotech catalysts?→

Add NVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Novo Nordisk A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply